Extending Current Guideline-recommended Prostate-specific Antigen Density Thresholds for Improving Benefit/Harm Balance in Risk-based Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis, from the Community-based Multicentre MR-PROPER Study.
Prinsen AMA, Wagensveld IM, Osses DF, Groenendijk PM, Zijta FM, Busstra MB, Rociu E, Barentsz JO, Sedelaar JPM, Arbeel B, Roeleveld T, Geenen R, Koeter I, van der Meer S, Cappendijk VC, Klaver S, van der Lely H, Wolters T, Leter MR, van der Poel HG, Heijmink SWTPJ, Immerzeel J, Leijte JAP, van Roermund JGH, Miclea RL, Planken E, Vis AN, de Jong IJ, Tijsterman J, Wolterbeek D, Claessen A, Nederend J, Bangma CH, Roobol MJ, Remmers S, van den Bergh RCN, Somford DM, Schoots IG.
Prinsen AMA, et al.
Eur Urol Oncol. 2025 Nov 28:S2588-9311(25)00290-1. doi: 10.1016/j.euo.2025.11.002. Online ahead of print.
Eur Urol Oncol. 2025.
PMID: 41318235
Free article.